<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin J Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">Chin J Cancer Res</journal-id><journal-id journal-id-type="pmc-domain-id">1997</journal-id><journal-id journal-id-type="pmc-domain">cjcr</journal-id><journal-id journal-id-type="publisher-id">zgazyj</journal-id><journal-title-group><journal-title>Chinese Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="ppub">1000-9604</issn><issn pub-type="epub">1993-0631</issn><publisher><publisher-name>Beijing Institute for Cancer Research</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12780783</article-id><article-id pub-id-type="pmcid-ver">PMC12780783.1</article-id><article-id pub-id-type="pmcaid">12780783</article-id><article-id pub-id-type="pmcaiid">12780783</article-id><article-id pub-id-type="doi">10.21147/j.issn.1000-9604.2025.06.02</article-id><article-id pub-id-type="publisher-id">cjcr-37-6-882</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Epidemiology, early detection, and management of breast cancer in China: A comprehensive review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="H">Hangcheng</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Xu</surname><given-names initials="B">Binghe</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp">*</xref><email>xubh@cicams.ac.cn</email></contrib></contrib-group><aff id="aff1">
<addr-line>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China</addr-line>
</aff><author-notes><corresp id="cor1">Binghe Xu, MD. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing 100021, China. Email: <email>xubh@cicams.ac.cn</email></corresp></author-notes><pub-date pub-type="ppub"><day>30</day><month>12</month><year>2025</year></pub-date><volume>37</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">504567</issue-id><fpage>882</fpage><lpage>899</lpage><history><date date-type="received"><day>15</day><month>10</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-09 00:25:13.010"><day>09</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>&#169; Chinese Journal of Cancer Research. All rights reserved.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Chinese Journal of Cancer Research</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cjcr-37-6-882.pdf"/><abstract><p>Breast cancer represents a significant and growing public health challenge in China, marked by a rising incidence and distinct variations across age groups and geographical regions. This review synthesizes recent evidence regarding the epidemiology, early detection, and early treatment in the Chinese context. We outline current patterns of disease burden and the spectrum of risk factors&#8212;both modifiable and non-modifiable. We note ongoing shifts linked to reproductive trends, lifestyle changes, and an aging population. Screening practices are increasingly evolving towards stratified, risk-adapted pathways. These approaches often combine mammography with adjunct imaging modalities such as ultrasound, digital breast tomosynthesis, or magnetic resonance imaging for selected populations, while artificial intelligence is under active investigation to enhance image interpretation and streamline workflow. Contemporary early management strategies emphasize breast-conserving surgery and selective axillary surgery, alongside the expanded application of hypofractionated and precision-targeted radiotherapy. Systemic therapy is increasingly guided by tumor subtype. In the adjuvant setting, molecular profiling and multigene assays are now routinely utilized to tailor treatment intensity to individual tumor biology, facilitating both treatment escalation or de-escalation where appropriate. Concurrently, in the neoadjuvant setting, research efforts within China and globally are focused on evaluating novel therapeutic regimens and biomarker-driven strategies to improve pathologic complete response rates and inform subsequent postoperative care. A consolidated understanding of these evolving themes is crucial for shaping effective clinical practice and health policies, ultimately supporting the goals of earlier diagnosis and improved patient outcomes in China.</p></abstract><kwd-group kwd-group-type="author-created"><kwd>Breast cancer</kwd><kwd>epidemiology</kwd><kwd>risk factors</kwd><kwd>early detection</kwd><kwd>early treatment</kwd></kwd-group><funding-group><funding-statement>This work was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2021-I2M-1-014 and No. 2022-I2M-2-002) and National High Level Hospital Clinical Research Funding (2025-LYZX-D-A02).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>